Organoidsciences Ltd. (KOSDAQ:476040)

South Korea flag South Korea · Delayed Price · Currency is KRW
22,950
-650 (-2.75%)
At close: Apr 28, 2026
-9.65%
Market Cap 151.14B
Revenue (ttm) 2.41B
Net Income (ttm) -15.37B
Shares Out 6.59M
EPS (ttm) -2,517.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 57,238
Average Volume 88,217
Open 23,650
Previous Close 23,600
Day's Range 22,850 - 23,650
52-Week Range 20,250 - 52,000
Beta n/a
RSI 43.63
Earnings Date Apr 10, 2026

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476040
Full Company Profile

Financial Performance

In 2025, Organoidsciences's revenue was 2.41 billion, an increase of 23.21% compared to the previous year's 1.95 billion. Losses were -15.37 billion, 36.6% more than in 2024.

Financial Statements

News

There is no news available yet.